Search

Your search keyword '"DEL PRATO, Stefano"' showing total 1,623 results
Start Over Author "DEL PRATO, Stefano"
1,623 results on '"DEL PRATO, Stefano"'

201. List of contributors

Author

Ajjan, Ramzi A., Balasubramanian, Priyadarshini, Bashir, Bilal, Chew, Nicholas W.S., Chilton, Robert J., Climie, Rachel E.D., Del Prato, Stefano, Dobre, Mirela, Falcetta, Pierpaolo, Fan, Wenjun, Santos-Ferreira, Diogo, Garofolo, Monia, Garvey, William T., Grant, Peter J., Harfouch, Badr, Heiss, Christian, Ho, Kim L., Holst, Jens Juul, Inzucchi, Silvio E., Iqbal, Zohaib, Jacob, Stephan, Kietsiriroje, Noppadol, Kopecky, Steve, Krentz, Andrew J., Leschke, Matthias, Lopaschuk, Gary D., Lubberding, Anniek Frederike, Madsbad, Sten, Leite-Moreira, Adelino, Moreira, Emília, Muthiah, Mark D., Neeland, Ian J., Nilsson, Peter M., Penno, Giuseppe, Sanyal, Arun J., Schofield, Jonathan, Silva-Cardoso, José, Solis-Herrera, Carolina, Soran, Handrean, Triplitt, Curtis, and Wong, Nathan D.

Published
2023
Full Text
View/download PDF

214. New-Onset Diabetes in Covid-19

Author

Rubino, Francesco, primary, Amiel, Stephanie A., additional, Zimmet, Paul, additional, Alberti, George, additional, Bornstein, Stefan, additional, Eckel, Robert H., additional, Mingrone, Geltrude, additional, Boehm, Bernhard, additional, Cooper, Mark E., additional, Chai, Zhonglin, additional, Del Prato, Stefano, additional, Ji, Linong, additional, Hopkins, David, additional, Herman, William H., additional, Khunti, Kamlesh, additional, Mbanya, Jean-Claude, additional, and Renard, Eric, additional

Published
2020
Full Text
View/download PDF

215. Insulin Resistance and Risk of Major Vascular Events and All-Cause Mortality in Type 1 Diabetes: A 10-Year Follow-up Study

Author

Garofolo, Monia, primary, Gualdani, Elisa, additional, Scarale, Maria Giovanna, additional, Bianchi, Cristina, additional, Aragona, Michele, additional, Campi, Fabrizio, additional, Lucchesi, Daniela, additional, Daniele, Giuseppe, additional, Miccoli, Roberto, additional, Francesconi, Paolo, additional, Del Prato, Stefano, additional, and Penno, Giuseppe, additional

Published
2020
Full Text
View/download PDF

218. Impact of disease duration and β‐cell reserve on the efficacy of switching toiGlarLixiin adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from theLixiLan‐Gtrial

Author

Del Prato, Stefano, primary, Frias, Juan Pablo, additional, Blonde, Lawrence, additional, Aroda, Vanita R., additional, Shehadeh, Niam, additional, Saremi, Aramesh, additional, Dex, Terry, additional, Niemoeller, Elisabeth, additional, Souhami, Elisabeth, additional, Liu, Minzhi, additional, and Rosenstock, Julio, additional

Published
2020
Full Text
View/download PDF

224. Triglyceride concentrations and non-high-density lipoprotein cholesterol goal attainment in the ODYSSEY phase 3 trials with alirocumab

Author

Vallejo-Vaz, Antonio J, primary, Leiter, Lawrence A, additional, Del Prato, Stefano, additional, Taskinen, Marja-Riitta, additional, Müller-Wieland, Dirk, additional, Bujas-Bobanovic, Maja, additional, Letierce, Alexia, additional, Mandel, Jonas, additional, Samuel, Rita, additional, and Ray, Kausik K, additional

Published
2020
Full Text
View/download PDF

225. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

Author

Colhoun, Helen M., primary, Leiter, Lawrence A., additional, Müller-Wieland, Dirk, additional, Cariou, Bertrand, additional, Ray, Kausik K., additional, Tinahones, Francisco J., additional, Domenger, Catherine, additional, Letierce, Alexia, additional, Israel, Marc, additional, Samuel, Rita, additional, and Del Prato, Stefano, additional

Published
2020
Full Text
View/download PDF

230. Altered Visual Plasticity in Morbidly Obese Subjects

Author

Lunghi, Claudia, primary, Daniele, Giuseppe, additional, Binda, Paola, additional, Dardano, Angela, additional, Ceccarini, Giovanni, additional, Santini, Ferruccio, additional, Del Prato, Stefano, additional, and Morrone, Maria Concetta, additional

Published
2019
Full Text
View/download PDF

231. Microvascular complications burden (nephropathy, retinopathy and peripheral polyneuropathy) affects risk of major vascular events and all-cause mortality in type 1 diabetes: a 10-year follow-up study

Author

Garofolo, Monia, primary, Gualdani, Elisa, additional, Giannarelli, Rosa, additional, Aragona, Michele, additional, Campi, Fabrizio, additional, Lucchesi, Daniela, additional, Daniele, Giuseppe, additional, Miccoli, Roberto, additional, Francesconi, Paolo, additional, Del Prato, Stefano, additional, and Penno, Giuseppe, additional

Published
2019
Full Text
View/download PDF

233. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies

Author

Ray, Kausik K., primary, Del Prato, Stefano, additional, Müller-Wieland, Dirk, additional, Cariou, Bertrand, additional, Colhoun, Helen M., additional, Tinahones, Francisco J., additional, Domenger, Catherine, additional, Letierce, Alexia, additional, Mandel, Jonas, additional, Samuel, Rita, additional, Bujas-Bobanovic, Maja, additional, and Leiter, Lawrence A., additional

Published
2019
Full Text
View/download PDF

234. How Do We Define Cure of Diabetes?

Author

Buse, John B., Caprio, Sonia, Cefalu, William T., Ceriello, Antonio, Del Prato, Stefano, Inzucchi, Silvio E., McLaughlin, Sue, Phillips, Gordon L., II, Robertson, R. Paul, Rubino, Francesco, Kahn, Richard, and Kirkman, M. Sue

Published
2009

237. Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk

Author

Müller-Wieland, Dirk, Leiter, Lawrence A., Cariou, Bertrand, Letierce, Alexia, Colhoun, Helen M., Del Prato, Stefano, Henry, Robert R., Tinahones, Francisco J., Aurand, Lisa, Maroni, Jaman, Ray, Kausik K., and Bujas-Bobanovic, Maja

Subjects
Non-HDL-C, lcsh:Diseases of the circulatory (Cardiovascular) system, Time Factors, Alirocumab, Diabetes, Mixed dyslipidaemia, ODYSSEY, PCSK9, Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine, Hyperlipoproteinemia Type V, Antibodies, Monoclonal, Humanized, 1102 Cardiovascular Medicine And Haematology, Endocrinology, Clinical Protocols, Journal Article, Humans, Original Investigation, Anticholesteremic Agents, PCSK9 Inhibitors, Antibodies, Monoclonal, nutritional and metabolic diseases, Diabetes and Metabolism, Editorial, Cholesterol, Treatment Outcome, Cardiovascular System & Hematology, Diabetes Mellitus, Type 2, Research Design, lcsh:RC666-701, lipids (amino acids, peptides, and proteins), Proprotein Convertase 9, Biomarkers
Abstract

Cardiovascular diabetology 16(1), 70 (2017). doi:10.1186/s12933-017-0552-4, Published by BioMed Central, London

Published
2017

242. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/ mortality? Yes

Author

Bianchi, Cristina, Miccoli, Roberto, Daniele, Giuseppe, Penno, Giuseppe, and Del Prato, Stefano

Subjects
Hypoglycemic agents -- Dosage and administration -- Research -- Complications and side effects, Cardiovascular diseases -- Risk factors -- Research -- Complications and side effects -- Drug therapy, Type 2 diabetes -- Drug therapy -- Complications and side effects -- Research -- Risk factors, Health
Abstract

A though type 2 diabetes is a heterogeneous condition encompassing multiple metabolic and vascular alterations, it can be easily described as a disease characterized by chronic hyperglycemia and increased cardiovascular [...]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results